Published in N Engl J Med on March 14, 2010
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620
VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis | NCT00035711
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) (RCT-IVVE) | NCT02762851
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot (IVVE:Pilot) | NCT01945268
Fenofibrate Intervention as COVID-19 Therapy (FERMIN) | NCT04517396
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Diabetes in older adults: a consensus report. J Am Geriatr Soc (2012) 3.63
Diabetes in older adults. Diabetes Care (2012) 3.62
Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet (2014) 3.53
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol (2012) 3.11
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med (2012) 2.95
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int (2016) 2.91
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med (2014) 2.25
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
Dyslipidemia in obesity: mechanisms and potential targets. Nutrients (2013) 2.02
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology (2014) 1.89
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J (2014) 1.82
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician (2013) 1.67
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J (2013) 1.60
Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med (2013) 1.51
Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension (2015) 1.49
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes (2014) 1.44
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism (2011) 1.41
The role of triglycerides in atherosclerosis. Curr Cardiol Rep (2011) 1.38
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol (2010) 1.35
Fish oils, coronary heart disease, and the environment. Am J Public Health (2013) 1.29
Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues. Diabetes Care (2010) 1.20
Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol (2011) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Combination lipid therapy in type 2 diabetes. N Engl J Med (2010) 1.20
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View. Clin J Am Soc Nephrol (2015) 1.18
The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol (2012) 1.17
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care (2012) 1.14
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract (2010) 1.13
Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep (2012) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.10
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis (2011) 1.08
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care (2011) 1.08
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol (2010) 1.07
Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A (2013) 1.07
The Role of PPARα Activation in Liver and Muscle. PPAR Res (2010) 1.07
Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care (2012) 1.07
Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment. Circ Cardiovasc Qual Outcomes (2012) 1.06
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets (2012) 1.04
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring) (2013) 1.04
Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med (2010) 1.04
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol (2012) 1.03
Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord (2012) 1.03
Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc (2013) 1.03
Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets (2010) 1.01
The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis (2012) 1.01
Lipid-lowering therapy: who can benefit? Vasc Health Risk Manag (2011) 1.01
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab (2011) 1.00
Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol (2014) 1.00
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care (2016) 1.00
ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med (2010) 0.99
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci (2013) 0.99
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care (2013) 0.99
Diabetes and its comorbidities--where East meets West. Nat Rev Endocrinol (2013) 0.99
Longitudinal Patterns of Blood Pressure, Incident Cardiovascular Events, and All-Cause Mortality in Normotensive Diabetic People. Hypertension (2016) 0.98
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J (2012) 0.98
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care (2013) 0.98
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Overview of omega-3 Fatty Acid therapies. P T (2013) 0.97
Cardiovascular risk. Br J Clin Pharmacol (2012) 0.97
Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl (2013) 0.96
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye (Lond) (2011) 0.96
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care (2011) 0.96
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J (2013) 0.96
Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies. Cardiovasc Diabetol (2012) 0.96
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care (2016) 0.95
Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud (2013) 0.95
Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis (2010) 0.95
Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med (2012) 0.95
Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine (2014) 0.95
Albuminuria and cognitive decline in people with diabetes and normal renal function. Clin J Am Soc Nephrol (2013) 0.95
Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes Metab J (2015) 0.94
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol (2012) 0.94
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 17.66
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 13.69
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ (1998) 7.48
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 4.96
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation (2000) 4.87
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med (2004) 3.34
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 3.29
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care (1998) 2.70
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med (2002) 2.59
Diabetic dyslipidemia. Endocrinol Metab Clin North Am (2006) 2.35
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol (2005) 2.16
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol (2004) 1.47
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol (2004) 1.46
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab (2008) 7.97
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA (2012) 6.29
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation (2007) 5.87
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care (2009) 5.41
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation (2009) 5.26
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78